Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila lipid fraction
- Development stage
- Preclinical
- Lead developer
- University of California, Los Angeles
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Intraperitoneal
01
Overview
Akkermansia muciniphila lipid fraction (also known as AMF1) is a purified microbial lipid fraction derived from the gut commensal bacterium *Akkermansia muciniphila*. Developed by researchers at the University of California, Los Angeles (UCLA), AMF1 is being investigated for its potential to protect against hepatocellular injury and acute sterile hepatic inflammation, such as that associated with liver transplantation and ischemia-reperfusion injury. In preclinical murine models of lipopolysaccharide (LPS)/D-galactosamine-induced acute liver injury, administration of AMF1 significantly improved liver histology, reduced Suzuki's injury scores, lowered serum alanine aminotransferase (ALT) levels, decreased the frequency of apoptotic cells, and suppressed the expression of the pro-inflammatory chemokine Cxcl2. These findings suggest that *A. muciniphila*-derived lipid metabolites could serve as refined therapeutics to enhance graft resilience and improve post-liver transplant outcomes.
- Other names
- Akkermansia muciniphila-derived lipid fraction
02
Targets
CXCL2 (C-X-C motif chemokine ligand 2)IL-6 (Interleukin 6)TLR1TLR2 (Toll-like Receptor 2)TLR6
Beyond the preview
Go deeper on Akkermansia muciniphila lipid fraction.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila lipid fraction.